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Original article
Secukinumab provides sustained low rates of
radiographic progression in psoriatic arthritis:
52-week results from a phase 3 study, FUTURE 5
Désirée van der Heijde 1, Philip J. Mease2, Robert B.M. Landewé3,
Proton Rahman4, Hasan Tahir5, Atul Singhal6, Elke Boettcher7, Sandra Navarra8,
Xuan Zhu9, Gregory Ligozio9, Aimee Readie9, Shephard Mpofu10 and
Luminita Pricop9
Abstract
Objective. To evaluate the effect of secukinumab on radiographic progression through 52 weeks in patients with PsA
from the FUTURE 5 study.
Methods. Patients with active PsA, stratified by prior anti-TNF use (naı̈ve or inadequate response), were randomized to
s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks
1, 2 and 3 and every 4 weeks starting at week 4. Radiographic progression was assessed by change in van der Heijde-
modified total Sharp score (vdH-mTSS; mean of two readers). Statistical analysis used a linear mixed-effects model
(random slope) at weeks 24 and 52, and observed data at week 52. Assessments at week 52 included additional efficacy
endpoints (non-responders imputation and mixed-effects models for repeated measures) and safety.
Results. The majority (86.6%) of patients completed 52 weeks of treatment. The proportion of patients with no radio-
graphic progression (change from baseline in vdH-mTSS 40.5) was 91.8, 85.2 and 87.2% in 300, 150 and 150 mg no
load groups, respectively, at week 52. The change in vdH-mTSS from baseline to week 52 using random slope [mean
change (S.E.)] was 0.18 (0.17), 0.11 (0.18) and 0.20 (0.18) in 300, 150 and 150 mg no load groups, respectively; the
corresponding observed data [mean change (S.D.)] was 0.09 (1.02), 0.13 (1.39) and 0.21 (1.15). Clinical efficacy end-
points were sustained, and no new or unexpected safety signals were reported through 52 weeks.
Conclusion. Secukinumab 300 and 150 mg with or without s.c. loading regimen provided sustained low rates of
radiographic progression through 52 weeks of treatment.
Trial registration. ClinicalTrials.gov, http://clinicaltrials.gov, NCT02404350.
Key words: spondylarthropathies (including psoriatic arthritis), biological therapies, immunotherapy, cytokines
and inflammatory mediators, inflammation, pain assessment and management
Rheumatology key messages
. Secukinumab demonstrated sustained low rates of radiographic progression through 52 weeks of treatment.
. The proportion of patients with no radiographic progression ranged from 85 to 92% in this large PsA study.
. Secukinumab-treated patients reported comparable radiographic data independent of the statistical method
applied.
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PsA is a chronic inflammatory peripheral arthritis asso-
ciated with axial disease, dactylitis, enthesitis, skin and
nail psoriasis, physical disability, and reduced health-
related quality of life [1, 2]. More prominently, it is asso-
ciated with structural changes to the joints (erosive or pro-
liferative bone changes, erosive joint destruction, joint
space narrowing, fluffy periostitis and pencil-in-cup defor-
mities), which are detected and characterized radiograph-
ically [35]. Approximately 50% of PsA patients are
diagnosed with erosive joint destruction within 2 years of
disease onset [6]. Assessment of radiographic disease
progression in PsA is an important outcome from a clinical
perspective, to assess disease severity and to quantify the
effect of treatment on disease progression [7]. IL-17A
plays a crucial role in the pathogenesis of PsA; structural
damage and radiographic disease progression are
strongly correlated with the presence of IL-17A-producing
immune cells at the inflamed joints [810].
Secukinumab, a human monoclonal IgG1k antibody
that directly inhibits IL-17A, has demonstrated rapid and
sustained efficacy in patients with PsA across Phase 3
FUTURE studies [1114]. Secukinumab 300 and 150 mg
s.c. doses have been approved for treatment of PsA. In
the FUTURE 1 study, secukinumab 150 mg reported sus-
tained clinical responses with a low rate of radiographic
progression over 3 years [15]. In FUTURE 5, secukinumab
300 and 150 mg s.c. dosing regimens significantly lowered
the rate of radiographic disease progression vs placebo at
week 24 [12]. Herein, we present the effects of secukinu-
mab 300 and 150 mg dosing regimens on radiographic
disease progression through 52 weeks from the FUTURE
5 study.
Methods
Patients and study design
FUTURE 5 (NCT02404350) is an ongoing randomized pla-
cebo-controlled 2-year Phase 3 trial. The detailed inclu-
sion and exclusion criteria and study design have been
reported previously [12]. Patients 518 years of age, fulfill-
ing the CASPAR (ClASsification criteria for Psoriatic
ARthritis) criteria [16], with symptoms of active PsA for
at least 6 months: three or more tender joints (TJC) and
three or more swollen joints (SJC) despite treatment with
NSAIDs, conventional synthetic DMARDs (csDMARDs)
and/or anti-TNF agents. Concomitant use of glucocortic-
oids (410 mg/day), NSAIDs and MTX (425 mg/week)
were allowed. Patients with an inadequate response (IR)
or who stopped treatment due to safety or intolerance to
an anti-TNF agent (hereafter collectively referred as anti-
TNF-IR) were included in this study. Key exclusion criteria
included active/history of ongoing infection, prior use of a
biologic other than an anti-TNF agent, use of greater than
three different anti-TNF agents and active inflammatory
disease other than PsA.
Eligible patients were randomized (2:2:2:3) to one of four
treatment groups: self-administered s.c. secukinumab
300 mg with loading dose (300 mg), 150 mg with loading
dose (150 mg), 150 mg without loading dose (150 mg no
load) or placebo. All patients received s.c. secukinumab
300 mg, 150 mg or placebo at baseline, at weeks 1, 2 and
3, and every 4 weeks starting at week 4. Patients, investi-
gators and assessors remained blinded to the treatment
assignment until all patients reached the week 52 visit. At
week 16, non-responders (<20% reduction in TJC and/or
SJC) in the placebo group were switched to s.c. secukinu-
mab 300 or 150 mg and all remaining patients (responders)
on placebo were switched at week 24. Patients were stra-
tified according to prior use of anti-TNF therapy status [i.e.
patients who were naı̈ve to anti-TNF therapy (anti-TNF-
naı̈ve) vs those who were anti-TNF-IR]. The study was
planned to enrol no more than 30% anti-TNF-IR patients.
The study was conducted in accordance with the
Declaration of Helsinki [17] and was approved by institu-
tional review boards or independent ethics committees at
each participating centre. Written informed consent was
obtained from all enrolled patients. Data were collected in
accordance with Good Clinical Practice guidelines by the
study investigators and were analysed by the sponsor.
Data presented here are from the week 52 (1 year) analysis
of the study.
Efficacy outcomes
Radiographic disease progression was assessed by
change from baseline in van der Heijde-modified total
Sharp score [vdH-mTSS; sum of bone erosion (05 in
the hands and 010 in the feet) and joint space narrowing
(04) scores] for PsA [18]. Radiographic scores were as-
sessed from two reading sessions: reading session 1:
baseline, weeks 16 and 24; and reading session 2: base-
line, weeks 16, 24 and 52. The vdH-mTSS assessment
was based on hands/wrists/feet radiographs obtained
from reading session 1 for 24-week analysis and from
reading session 2 for 52-week analysis. Mean scores
were assessed by two blinded readers independently (if
there was an adjudicator involved then three readers were
used) who were blinded to all patient information, treat-
ment allocation and order of radiographs. The total radio-
graphic score (hands and feet combined) ranged from 0 to
528, with higher scores indicating more articular damage.
Data are shown for weeks 24 and 52. As recommended
by van der Heijde et al., a change from baseline in vdH-
mTSS 40.5 was used to define no structural progression;
the proportion of patients with no structural progression
was determined [18] at week 52.
Other assessments at week 52 included the ACR 20, 50
and 70 responses, Psoriasis Area and Severity Index 75
and 90 responses, mean change from baseline in
HAQDisability Index, 28-joint DAS using CRP (DAS28-
CRP), and Short Form 36 Physical Component Summary
Score (SF-36 PCS), and resolution of enthesitis and dac-
tylitis [1925].
Pre-specified subgroup analyses based on previous
use of anti-TNF therapy status (naı̈ve vs IR) on radio-
graphic disease progression was also performed.
1326 https://academic.oup.com/rheumatology
Désirée van der Heijde et al.
Overall safety and tolerability of secukinumab over the
52 weeks was assessed by monitoring adverse events




At week 52, data are presented by linear mixed-effects
model (random intercept and random slopes, which will
be referred to as random slope hereafter) and as observed
analysis. The random slope model at week 52 included
patients with baseline and at least one post-baseline
radiographic assessment (evaluable radiographs) from
week 16, 24 or 52. Observed analysis included patients
who had radiographic assessments at baseline and week
52.
The 24-week analysis
In addition to week 52, data at week 24 are presented
using linear extrapolation and random slope models.
Linear extrapolation and random slope analyses at week
24 included patients with baseline and at least one post-
baseline radiographic assessment from week 16 or 24.
This 24-week linear extrapolation was reanalysed after
an incorrect mapping of the radiographic data was identi-
fied in the interim analysis.[12] It was confirmed that 10/
936 (1.1%) patients with baseline and post-baseline radio-
graphs were impacted by the incorrect mapping and were
included in this 24-week linear extrapolation reanalysis.
Statistical analyses
Data are presented for patients originally randomized to
secukinumab and placebo. In the linear mixed-effects
model, the random slope and random intercept was
used to calculate the changes in radiographic structural
progression score over 52 weeks. The week 24 random
slope excluded data after escape for placebo patients
who received escape therapy at week 16. The model
assumed approximately linear progression over time and
estimated a difference in rates (slopes) of progression
over 52 weeks to compare treatment arms. The model
accounted for covariates of time, treatment, treatment-
by-time interaction, baseline mTSS score, body weight
and prior anti-TNF status.
The linear extrapolation approach used the change rate
from baseline to week 16 to impute the missing change
rate for week 24; that is, for patients who met the criteria
for early escape at week 16 and did not have week 24
measurement on the same treatment. Linear extrapolation
was used to impute the missing values at week 24 if at
least two assessments existed before week 24 (including
baseline assessment).
Cumulative probability plot was generated as described
previously [26] to show the vdH-mTSS for all patients ac-
cording to dose group from baseline to week 52.
Clinical efficacy analyses used logistic regression for
binary variables, and mixed-effects models for repeated
measures (MMRM) for continuous variables. All analyses
included treatment and randomization stratum (anti-TNF
status) as a factor (time, treatment-by-time and baseline-
by-time interaction were also used for MMRM), and body
weight and the corresponding baseline value as a covari-
ate. Missing values and placebo patients rescued at week
16 were imputed as non-responders for binary variables
(rescue penalty) and the missing at random assumption of
the MMRM analysis was applied for continuous variables.
Safety analysis included all patients who received one
or more dose of study drug and were summarized de-
scriptively. Patients were evaluated according to the treat-
ment they received. All analyses were computed with SAS
version 9.4.
Results
Of the 996 patients randomized at baseline, 86.6% (862/
996) completed 52 weeks of treatment [300 mg: 91.9%
(204/222), 150 mg: 91.4% (201/220), 150 mg no load:
86.9% (193/222) and placebo-secukinumab: 79.5%
(264/332)]. A total of 108 (10.8%) patients discontinued
before or at week 52. The detailed disposition up to
week 52 including reasons for discontinuation is pre-
sented in Fig. 1. Demographics and baseline disease
characteristics were balanced between treatment arms
and have been reported previously [12]. At baseline,
70% of patients were anti-TNF-naı̈ve and 50% were
receiving concomitant MTX. The number of patients with
evaluable radiographs at both baseline and week 52 were
as follows: 207 (93.2%) in 300 mg, 203 (92.3%) in 150 mg
and 195 (87.8%) in 150 mg no load. The number of pa-
tients included in the linear extrapolation and random
slope analyses at week 24 were: 217 (97.7%) in the
300 mg, 213 (96.8%) in 150 mg, 210 (94.6%) in 150 mg
no load and 296 (89.2%) in the placebo group.
Efficacy
Radiographic progression
In the overall population, the radiographic progression
rate was low at week 52 across all treatment groups.
Mean changes from baseline in vdH-mTSS using
observed data and random slope analysis at week 52
are presented in Fig. 2A. Random slope data (S.E.)
showed numerically lower progression in the 300 mg
[0.18 (0.17)] and 150 mg no load [0.20 (0.18)] groups
compared with the 150 mg [0.11 (0.18)] group. Observed
data (S.D.) showed lower [0.09 (1.02)] progression in the
300 mg group compared with the 150 [0.13 (1.39)] and
150 mg no load [0.21 (1.15)] groups.
Mean changes (S.D.) from baseline in vdH-mTSS by
linear extrapolation were 0.02 (1.34; P < 0.001), 0.13
(1.22; P < 0.01) and 0.10 (2.87; P < 0.01) in the 300,
150 and 150 mg no load groups, respectively, vs 0.50
(1.71) in the placebo group at week 24 (Fig. 2B).
Corresponding mean changes (S.E.) from baseline by
random slope analysis were very similar, with 0.03 (0.13;
P < 0.01), 0.14 (0.13; P < 0.05) and 0.10 (0.13; P <
0.001), respectively, vs 0.51 (0.11) at week 24 (Fig. 2B).
https://academic.oup.com/rheumatology 1327
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In patients with prior anti-TNF therapy status, the mean
changes from baseline in vdH-mTSS by random slope,
observed data and linear extrapolation analyses followed
a similar trend of low radiographic progression to that in
the overall population (Fig. 2A and B). The anti-TNF-naı̈ve
group showed lower progression than the anti-TNF-IR
group.
Additionally, the mean changes from baseline at week
24 in vdH-mTSS by linear extrapolation from patients with
baseline and at least one post-baseline radiographic
FIG. 2 Mean changes from baseline in vdH-mTSS
*P < 0.001; **P < 0.01; ***P < 0.05 un-adjusted P-values versus placebo (P-values are from non-parametric ANCOVA).
Overall population: N = 222, 220, 222 and 332; anti-TNF-naı̈ve: N = 154, 155, 158 and 234; anti-TNF-IR: N = 68, 65, 64
and 98 patients in secukinumab 300 mg, 150 mg, 150 mg no load and placebo groups, respectively. IR: inadequate
response; N: total number of patients randomized; n: number of patients included in the linear extrapolation and random
slope at week 24 and evaluable patients at week 52; vdH-mTSS: van der Heijde-modified total Sharp score.
FIG. 1 Patient disposition through week 52
Patients received s.c. secukinumab 300 or 150 mg, or placebo at baseline, weeks 1, 2 and 3, and every 4 weeks starting
at week 4. Patients in the 150 mg no load arm were administered placebo at weeks 1, 2 and 3. At week 16, non-
responders (<20% reduction in TJC and/or SJC) in the placebo group were switched to s.c. secukinumab 300 or 150 mg
in a double-blind manner, and similarly, responders were switched at week 24. N: number of randomized patients; SJC:
swollen joint count; TJC: tender joint count.
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assessment from week 16, 24 or 52 are presented in sup-
plementary Fig. S1, available at Rheumatology online
(from reading session 2).
The proportion of patients with no radiographic pro-
gression (change from baseline in vdH-mTSS 40.5) with
secukinumab at week 52 were 91.8% (300 mg), 85.2%
(150 mg) and 87.2% (150 mg no load). Cumulative prob-
ability plots in vdH-mTSS change from baseline to week
52 showed the scores of the individual patients in the dif-
ferent secukinumab doses over 52 weeks of therapy
(Fig. 3). The findings in the pre-specified subgroup of pa-
tients by anti-TNF therapy status through 52 weeks were
similar. The proportion of anti-TNF-naı̈ve patients with no
radiographic progression at week 52 were: 94.6%
(300 mg), 85.7% (150 mg) and 88.7% (150 mg no load),
and in anti-TNF-IR patients were: 85.0% (300 mg),
83.9% (150 mg) and 83.3% (150 mg no load).
Clinical efficacy
The ACR20 response rates reported at week 16 [12] were
sustained through 52 weeks of secukinumab treatment. At
week 52, the ACR20 response was 68.9, 64.1 and 65.8%
in secukinumab 300, 150 and 150 mg no load groups, re-
spectively (Table 1). At week 52, the ACR20 response rate
in anti-TNF-naı̈ve patients was 72.7, 74.2 and 69.6% in
the secukinumab 300 mg, 150 mg and 150 mg no load
groups, respectively; in comparison, a numerically lower
response (60.3, 40.0 and 56.3%) was observed in anti-
TNF-IR patients (Table 1). In the overall population, the
least squares mean change (S.E.) from baseline in
DAS28-CRP score was 1.92 (0.07), 1.72 (0.07) and
1.83 (0.07) in the 300, 150 and 150 mg no load groups,
respectively, at week 52. Corresponding mean change in
SF-36 PCS score was 7.16 (0.46), 6.31 (0.46) and 7.03
(0.47), respectively, at week 52. Improvements reported
across all other efficacy endpoints at week 16 were also
sustained at week 52 (Table 1).
Safety
The safety data were consistent with that reported previ-
ously [12]. Over the entire treatment period, mean secuki-
numab exposure was 309.0 days (patient-years: 815.5).
The most commonly reported treatment-emergent AEs
were nasopharyngitis and upper respiratory tract infection
(Table 2). Most serious AEs represented single events with
no discernible pattern. Serious AE rates were low and com-
parable in both any secukinumab 300 mg (8.1%) and
150 mg (8.3%) dose groups. The rate of discontinuation
due to any AE was also low and comparable between
any secukinumab 300 mg (2.4%) and 150 mg (3.4%) dose
groups. The rate of selected AEs of interest are shown in
Table 2. No new or unexpected safety signals, no tubercu-
losis infections and no deaths were reported.
Discussion
This randomized placebo-controlled large Phase 3 study
of s.c. secukinumab 300 mg and 150 mg, with or without
FIG. 3 Cumulative probability plot in vdH-mTSS at week 52
The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS 40.5) with secukinu-
mab at week 52 were 91.8% (n = 207; 300 mg), 85.2% (n = 203; 150 mg) and 87.2% (n = 195; 150 mg no load).
Cumulative probability in each dose group in the range of 0 to 100%. The lower score indicates more inhibition achieved.
N: total number of patients randomized; n: number of evaluable patients; vdH-mTSS: van der Heijde-modified total Sharp
score.
https://academic.oup.com/rheumatology 1329


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Désirée van der Heijde et al.
loading regimen, demonstrated sustained low rates of
radiographic disease progression, with consistent clinical
efficacy and a favourable safety profile, in patients with
active PsA over 52 weeks of treatment. The majority (87%)
of patients enrolled at baseline remained in the study for
52 weeks, reflecting a high retention rate. The results re-
ported in this paper further substantiate previously pub-
lished data from the FUTURE 1 and 5 studies that
demonstrated significant and sustained inhibition of radio-
graphic progression in patients with PsA [12, 15].
Furthermore, this study validates the treatment effect of
secukinumab on radiographic disease progression by
utilizing different statistical methodologies to analyse the
radiographic data, and obtaining very similar results from
each of these methods. The radiographic assessment in
this study used random slope, evaluable radiograph and
linear extrapolation. The random slope analysis ac-
counted for more baseline covariates and handled statis-
tical uncertainty more robustly than single imputation,
which may be a preferred way of handing missing data.
The linear extrapolation approach handled inter-current
events (i.e. placebo escape patients’ data) and used lin-
earity to model vdH-mTSS over time. This model assumes
a linear rate of progression for all patients and uses single
imputation. However, the uncertainty surrounding the
missing data may not be sufficiently accounted for due
to slightly larger CIs.
The majority (8592%) of secukinumab-treated patients
in the overall population showed no radiographic progres-
sion at week 52. The vdH-mTSS were slightly different
between random slope and observed analyses presented
at week 52, with random slope analysis showing lower
radiographic progression scores across all secukinumab
doses compared with observed data. At week 24, the
vdH-mTSS showed significant reduction of radiographic
progression in secukinumab-treated patients compared
with placebo; the scores were almost identical across all
dose groups as measured by linear extrapolation and
random slope.
Similar to the overall population, low rates of radio-
graphic progression were also observed in secukinu-
mab-treated patients regardless of prior anti-TNF
therapy status. In the subgroup of TNF-naı̈ve patients,
there was a significant reduction of radiographic progres-
sion in the secukinumab-treated patients at week 24 com-
pared with placebo, which was lower through 52 weeks of
TABLE 2 Clinical safety with secukinumab during the entire treatment period through week 52a
Variable
Any secukinumab 300 mg Any secukinumab 150 mg
(N = 371)b (N = 593)b
Total exposure
Mean (S.D.) 298.5 (83.22) 315.5 (83.21)
Patient-years 303.2 512.2
Any AE, n (%) 259 (69.8) 436 (73.5)
Any SAE, n (%) 30 (8.1) 49 (8.3)
Discontinuation due to AE, n (%) 9 (2.4) 20 (3.4)
Death, n (%) 0 0
Most frequent AEs, n (EAIR per 100 patient-years)c
Nasopharyngitis 41 (14.4) 67 (14.1)
Upper respiratory tract infection 24 (8.2) 55 (11.4)
Hypertension 14 (4.7) 28 (5.6)
Diarrhoea 17 (5.8) 24 (4.8)
Influenza 16 (5.4) 15 (3.0)
Headache 10 (3.4) 25 (5.0)
Selected AEs of interest, n (EAIR per 100 patient-years)
Serious infections 5 (1.7) 8 (1.6)
Fungal infection 0 (0.0) 2 (0.4)
Candida infection (HLT) 9 (3.0) 9 (1.8)
Oral candidiasis 6 (2.0) 3 (0.6)
Ulcerative colitis 0 (0.0) 1 (0.2)
Crohn’s disease 0 (0.0) 2 (0.4)
MACE 1 (0.3) 1 (0.2)
Malignant/unspecified tumours 2 (0.7) 3 (0.6)
Neutropenia 3 (1.0) 8 (1.6)
aThe entire treatment period for safety data was from baseline through to the week 52 visit of each patient enrolled in this
study. bAny secukinumab group represents each originally randomized secukinumab patient plus placebo patients who
switched to active treatment at week 16 or 24. cAEs that occurred with an EAIR of at least 5.0 cases per 100 patient-
years in either any secukinumab 300 or 150 mg group over the entire treatment period. Events listed according to preferred
term in the Medical Dictionary for Regulatory Activities (MedDRA version 20.1), sorted in descending order of EAIR. AE:
adverse event; EAIR: exposure-adjusted incidence rate; HLT: high-level term; MACE: major adverse cardiovascular event;
N: total number of patients; SAE: serious adverse event.
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secukinumab treatment. In the (smaller) group of anti-
TNF-IR patients, higher progression was observed with
secukinumab compared with those observed in TNF-
naı̈ve patients. The lower response in the anti-TNF-IR
group may be attributed to a relatively small number pa-
tients and the heterogeneity of the anti-TNF subgroup,
which included patients with treatment failure due to
lack of efficacy, IR, intolerance or safety issues [27] with
anti-TNF therapies as specified in the inclusion criteria of
the current study. An additional reason may be that these
patients are harder to treat. Previous studies confirm the
inhibition of radiographic disease progression in PsA pa-
tients treated with anti-TNF agents [2832]. The radio-
graphic findings from the current study are aligned with
those reported in the anti-TNF trials and further establish
the therapeutic effect of secukinumab in patients with
PsA.
Sustained improvement was observed in secukinumab-
treated patients across all efficacy endpoints including
disease activity and physical function through week 52
in the overall population. Clinical improvements observed
at week 16 were sustained through 52 weeks of secukinu-
mab treatment, with numerically greater efficacy in anti-
TNF-naı̈ve vs -IR patients. The safety profile up to
52 weeks was consistent with that reported in prior secu-
kinumab trials [1114], with no new or unexpected safety
signals reported.
Limitations included that (i) this study was not designed
to identify a difference between treatment regimens (load
vs no load) or to assess treatment differences in response
to previous anti-TNF therapy status and (ii) the data pre-
sented in the anti-TNF-IR group should be interpreted with
caution due the small patient population.
In conclusion, this study demonstrated that secukinu-
mab 300 and 150 mg provided significant inhibition of
radiographic disease progression at week 24, with sus-
tained low rates of progression at week 52. This study
confirms the robustness of the radiographic data as
there is very low or minimal impact on the outcome irre-
spective of the statistical methodology used. These re-
sults extend previous findings confirming sustained low
rates of radiographic progression, clinical efficacy and
safety of secukinumab for the treatment of patients with
active PsA [1114].
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